A Phase 3, Randomized, Double-Blind, Active- and Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of CF101 Compared to Methotrexate in the Treatment of Early Rheumatoid Arthritis

Trial Profile

A Phase 3, Randomized, Double-Blind, Active- and Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of CF101 Compared to Methotrexate in the Treatment of Early Rheumatoid Arthritis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs Piclidenoson (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms ACROBAT
  • Sponsors Can-Fite BioPharma
  • Most Recent Events

    • 30 Oct 2017 According to a Can-Fite BioPharma media release, the first patient has been enrolled and dosed in this trial.
    • 30 Oct 2017 Status changed from not yet recruiting to recruiting according to a Can-Fite BioPharma media release.
    • 30 May 2017 According to a Can-Fite BioPharma media release, the company expects to commence this trial by the third quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top